Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2026)

Bristol Myers Squibb (BMY) has reported Change in Accured Expenses for 6 consecutive years, with $360.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 59.14% year-over-year to $360.0 million in Q2 2026; TTM through Jun 2026 was -$3.8 billion, a 329.62% decrease from a year earlier, with the FY2025 full-year figure at -$441.0 million, down 129.72% from the prior year.
• Change in Accured Expenses was $360.0 million for Q2 2026 at Bristol Myers Squibb, up from -$3.5 billion in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.8 billion in Q3 2024 and troughed at -$3.5 billion in Q1 2026.
• A 5-year average of -$42.3 million and a median of $74.5 million in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 141.86% in 2022, down 676.92% in 2022.
• Over 5 years, Change in Accured Expenses stood at -$303.0 million in 2022, then surged by 30.36% to -$211.0 million in 2023, then slumped by 91.94% to -$405.0 million in 2024, then plunged by 492.1% to -$2.4 billion in 2025, then jumped by 115.01% to $360.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $360.0 million (Q2 2026), -$3.5 billion (Q1 2026), and -$2.4 billion (Q4 2025), per Business Quant data.